| Follow us on Twitter |
(Amherst, NH) – In their search for methods to improve the way patients self-administer medications for chronic and refractory conditions, drug developers and healthcare sector stakeholder are increasingly turning to inhalation as a way to control costs and improve patient outcomes through increased compliance. By formulating drugs for delivery via the lung, developers avoid a host of issues associated with competing delivery methods. Device enhancements that make inhalation more intuitive while reducing patient-to-patient variability are adding to the appeal of pulmonary delivery at a time when a growing segment of the population in developed countries are reaching or approaching advanced age.
Advances in particle technology and the art of particle and aerosol flow dynamics are enabling an expanding number of drug APIs as potential candidates for inhaled drug delivery via dry powder inhalers, metered dose inhalers and new-generation nebulizers. Interest in dry powder inhalation is further benefiting from its ability to create stable dry particle forms of protein and peptide drugs that would otherwise require continuous refrigeration - the so-called ‘cold chain.’
Inhaled drug formulations are currently working their way through the clinical development process for more than a dozen new indications. The list includes several neurology conditions, metabolic disorders, inherited diseases, pain management, PAH, immunology and infectious diseases. Several of these inhaled drug candidates have the potential to impact the therapeutic markets they target, effectively changing the way important illnesses are treated.
Survey results are contained in a newly published report, researched and written by Greystone analysts. Delivering Drugs by Inhalation: Emerging Therapeutic Opportunities analyzes evolving inhaler technologies. emerging inhalation drug products, market participants, and key demand and technology factors influencing the commercial market and shaping growth in this sector.
More information is available at www.greystoneassociates.org .
About Greystone
Greystone Associates is a medical and healthcare technology consulting firm providing services in strategic planning, venture development, product commercialization, and technology and market assessment.
Contact:
Mark Smith
Voice: 603-595-4340
Fax: 603-804-0466
www.greystoneassociates.org
Source: Greystone Associates
Posted May 5th, 2008 by gstone
